Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 410

1.

Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?

Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI.

Cancer Epidemiol. 2018 Dec 5;58:83-88. doi: 10.1016/j.canep.2018.11.007. [Epub ahead of print]

PMID:
30528834
2.

More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder.

Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2018 Nov 17. pii: S1558-7673(18)30678-5. doi: 10.1016/j.clgc.2018.11.003. [Epub ahead of print]

PMID:
30527745
3.

Impact of adipose tissue on prostate cancer aggressiveness - analysis of a high-risk population.

Delouya G, Tiberi D, Bhatnagar SR, Campeau S, Saad F, Taussky D.

Horm Mol Biol Clin Investig. 2018 Nov 24. pii: /j/hmbci.ahead-of-print/hmbci-2018-0049/hmbci-2018-0049.xml. doi: 10.1515/hmbci-2018-0049. [Epub ahead of print]

PMID:
30471220
4.

North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients.

Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, Saad F, Soulières D, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Br J Cancer. 2018 Dec;119(12):1552-1556. doi: 10.1038/s41416-018-0323-3. Epub 2018 Nov 14.

PMID:
30425350
5.

Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.

Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI.

Clin Genitourin Cancer. 2018 Oct 4. pii: S1558-7673(18)30581-0. doi: 10.1016/j.clgc.2018.09.024. [Epub ahead of print]

PMID:
30366880
6.

Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.

Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, Suardi N, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2018 Sep 22. pii: S1558-7673(18)30185-X. doi: 10.1016/j.clgc.2018.09.011. [Epub ahead of print]

PMID:
30342845
7.

Tout le poids d'un nom, ou faut-il renommer notre spécialité?

Saad F.

Can Urol Assoc J. 2018 Oct;12(10):E428. doi: 10.5489/cuaj.5657. No abstract available.

8.

What's in a name? Renaming our specialty?

Saad F.

Can Urol Assoc J. 2018 Oct;12(10):298. doi: 10.5489/cuaj.5642. No abstract available.

9.

The effect of race on survival after local therapy in metastatic prostate cancer patients.

Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, Karakiewicz P.

Can Urol Assoc J. 2018 Oct 15. doi: 10.5489/cuaj.5399. [Epub ahead of print]

PMID:
30332592
10.

Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.

Targeted Alpha Therapy Working Group, Parker C, Lewington V, Shore N, Kratochwil C, Levy M, Lindén O, Noordzij W, Park J, Saad F.

JAMA Oncol. 2018 Dec 1;4(12):1765-1772. doi: 10.1001/jamaoncol.2018.4044.

PMID:
30326033
11.

Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States.

Preisser F, Nazzani S, Mazzone E, Knipper S, Bandini M, Tian Z, Haese A, Saad F, Zorn KC, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI.

World J Urol. 2018 Oct 12. doi: 10.1007/s00345-018-2525-y. [Epub ahead of print]

PMID:
30315358
12.

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer.

Sharma NV, Pellegrini KL, Ouellet V, Giuste FO, Ramalingam S, Watanabe K, Adam-Granger E, Fossouo L, You S, Freeman MR, Vertino P, Conneely K, Osunkoya AO, Trudel D, Mes-Masson AM, Petros JA, Saad F, Moreno CS.

Cancers (Basel). 2018 Oct 11;10(10). pii: E379. doi: 10.3390/cancers10100379.

13.

Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.

Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P.

Clin Cancer Res. 2018 Oct 9. pii: clincanres.0320.2018. doi: 10.1158/1078-0432.CCR-18-0320. [Epub ahead of print]

PMID:
30301829
14.

Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract.

Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI.

World J Urol. 2018 Oct 8. doi: 10.1007/s00345-018-2516-z. [Epub ahead of print]

PMID:
30298285
15.

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.

Tosco L, Briganti A, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K.

Eur Urol. 2019 Jan;75(1):44-60. doi: 10.1016/j.eururo.2018.07.027. Epub 2018 Oct 2. Review.

PMID:
30286948
16.

Enzalutamide in Castration-Resistant Prostate Cancer.

Hussain M, Saad F, Sternberg CN.

N Engl J Med. 2018 Oct 4;379(14):1381. doi: 10.1056/NEJMc1810065. No abstract available.

PMID:
30281993
17.

Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database.

Taussky D, Preisser F, Karakiewicz PI, Tilki D, Lambert C, Bahary JP, Delouya G, Wistaff R, Laskine M, Nguyen PV, Durand M, Saad F.

Can J Urol. 2018 Oct;25(5):9509-9515.

PMID:
30281009
18.

Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence.

Saad F, Pouliot F, Danielson B, Catton C, Kapoor A.

Can Urol Assoc J. 2018 Sep;12(9):E415-E420. doi: 10.5489/cuaj.5154. Epub 2018 May 14. Review.

19.

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.

Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, De Porre P, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K.

Eur J Cancer. 2018 Nov;103:78-87. doi: 10.1016/j.ejca.2018.08.010. Epub 2018 Sep 12.

20.

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.

Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.

PMID:
30213449

Supplemental Content

Loading ...
Support Center